Tamoxifen for relapse of ovarian cancer

Chris Williams, Iveta Simera, Andrew Bryant

Research output: Contribution to journalReview articlepeer-review

51 Citations (Scopus)


Tamoxifen is an important drug for treating breast cancer. Ovarian cancer cells are known to possess receptors for hormones and may thus also respond to tamoxifen.

Tamoxifen is used to treat breast cancer in women whose tumours have oestrogen receptors. Since ovarian cancers also commonly have oestrogen receptors, it has been suggested that tamoxifen may be of some benefit. The objective of this review was to assess the effects of tamoxifen in women with relapsed ovarian cancer.

Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Issue 1, 2009. Cochrane Gynaecological Cancer Group Trials Register, MEDLINE from 2002 to April 2009, EMBASE from 2002 to April 2009. We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of review articles and contacted experts in the field, as well as drugs companies.

Selection criteria
Randomised and non‐randomised studies of tamoxifen in women with ovarian cancer who have not responded to conventional chemotherapy. Only trials involving 10 or more patients were included.

Data collection and analysis
Two review authors independently assessed whether potentially relevant studies met the inclusion criteria. No trials were found and therefore no data were analysed.

Main results
The search strategy identified 1392 unique references of which 1360 were excluded on the basis of title and abstract. The remaining 32 articles were retrieved in full, but none satisfied the inclusion criteria. Only observational data from single arm studies of women treated with tamoxifen were reported.
Original languageEnglish
Number of pages17
JournalCochrane Database of Systematic Reviews
Issue number3
Publication statusPublished - 17 Mar 2010

Bibliographical note

Cited By :46

Export Date: 26 July 2021


Dive into the research topics of 'Tamoxifen for relapse of ovarian cancer'. Together they form a unique fingerprint.

Cite this